{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:08:34Z","timestamp":1793405314720,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Fosun Pharma, Shanghai, China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11523-025-01176-y","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:25:07Z","timestamp":1761485107000},"page":"991-1001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform Neurofibromas"],"prefix":"10.1007","volume":"20","clinical-trial-number":[{"clinical-trial-number":"nct04954001","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xiaojie","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghai","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Min","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,26]]},"reference":[{"key":"1176_CR1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-0660","author":"DT Miller","year":"2019","unstructured":"Miller DT, Freedenberg D, Schorry E, Ullrich NJ, Viskochil D, Korf BR, et al. Health supervision for children with neurofibromatosis type 1. Pediatrics. 2019;143(5):e20190660.","journal-title":"Pediatrics"},{"issue":"1","key":"1176_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13023-023-02911-2","volume":"18","author":"TJ Lee","year":"2023","unstructured":"Lee TJ, Chopra M, Kim RH, Parkin PC, Barnett-Tapia C. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet J Rare Dis. 2023;18(1):292.","journal-title":"Orphanet J Rare Dis"},{"key":"1176_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115850","author":"R Tamura","year":"2021","unstructured":"Tamura R. Current understanding of neurofibromatosis type 1, 2, and schwannomatosis. Int J Mol Sci. 2021;22(11):5850.","journal-title":"Int J Mol Sci"},{"key":"1176_CR4","first-page":"55","volume":"12","author":"C Copley-Merriman","year":"2021","unstructured":"Copley-Merriman C, Yang X, Juniper M, Amin S, Yoo HK, Sen SS. Natural history and disease burden of neurofibromatosis type 1 with plexiform neurofibromas: a systematic literature review. Adolesc Health Med Ther. 2021;12:55\u201366.","journal-title":"Adolesc Health Med Ther"},{"issue":"11","key":"1176_CR5","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","volume":"24","author":"MJ Fisher","year":"2022","unstructured":"Fisher MJ, Blakeley JO, Weiss BD, Dombi E, Ahlawat S, Akshintala S, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 2022;24(11):1827\u201344.","journal-title":"Neuro Oncol"},{"issue":"2","key":"1176_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/(SICI)1096-8628(19970516)70:2<138::AID-AJMG7>3.0.CO;2-U","volume":"70","author":"JM Friedman","year":"1997","unstructured":"Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet. 1997;70(2):138\u201343.","journal-title":"Am J Med Genet"},{"issue":"8","key":"1176_CR7","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00381-022-05513-8","volume":"38","author":"X Yang","year":"2022","unstructured":"Yang X, Yoo HK, Amin S, Cheng WY, Sundaresan S, Zhang L, et al. Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA. Childs Nerv Syst. 2022;38(8):1513\u201322.","journal-title":"Childs Nerv Syst"},{"issue":"15","key":"1176_CR8","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382(15):1430\u201342.","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"1176_CR9","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2024.42.16_suppl.3016","volume":"42","author":"CL Moertel","year":"2024","unstructured":"Moertel CL, Hirbe AC, Shuhaiber HH, Viskochil D, Sidhu A, Bielamowicz KJ, et al. ReNeu: a pivotal phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN). J Clin Oncol. 2024;42(16_suppl):3016.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1176_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12916-023-02927-2","volume":"21","author":"X Hu","year":"2023","unstructured":"Hu X, Li W, Zeng K, Xu Z, Li C, Kang Z, et al. Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas. BMC Med. 2023;21(1):230.","journal-title":"BMC Med"},{"issue":"21 Suppl 1","key":"1176_CR11","first-page":"S33","volume":"81","author":"E Dombi","year":"2013","unstructured":"Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG, et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology. 2013;81(21 Suppl 1):S33-40.","journal-title":"Neurology"},{"key":"1176_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2022.08.005","volume":"175","author":"L Mao","year":"2022","unstructured":"Mao L, Guo J, Zhu L, Jiang Y, Yan W, Zhang J, et al. A first-in-human, phase 1a dose-escalation study of the selective MEK1\/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma. Eur J Cancer. 2022;175:125\u201335.","journal-title":"Eur J Cancer"},{"key":"1176_CR13","doi-asserted-by":"publisher","first-page":"1101991","DOI":"10.3389\/fphar.2023.1101991","volume":"14","author":"Y Tan","year":"2023","unstructured":"Tan Y, Cui A, Qian L, Li C, Wu Z, Yang Y, et al. Population pharmacokinetics of FCN-159, a MEK1\/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics. Front Pharmacol. 2023;14:1101991.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1176_CR14","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s12325-022-02375-z","volume":"40","author":"J Li","year":"2023","unstructured":"Li J, Tan Y, Li K, Hui AM, Wu Z, Han P, et al. Effect of food (low and high fat) on pharmacokinetics of FCN-159, a selective MEK inhibitor, in healthy Chinese males. Adv Ther. 2023;40(3):1074\u201386.","journal-title":"Adv Ther"},{"key":"1176_CR15","unstructured":"US FDA. KOSELUGO (selumetinib) Product information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213756s000lbl.pdf."},{"issue":"9","key":"1176_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","volume":"68","author":"E Dombi","year":"2007","unstructured":"Dombi E, Solomon J, Gillespie AJ, Fox E, Balis FM, Patronas N, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology. 2007;68(9):643\u20137.","journal-title":"Neurology"},{"issue":"12","key":"1176_CR17","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","volume":"20","author":"AM Gross","year":"2018","unstructured":"Gross AM, Singh G, Akshintala S, Baldwin A, Dombi E, Ukwuani S, et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro Oncol. 2018;20(12):1643\u201351.","journal-title":"Neuro Oncol"},{"issue":"7","key":"1176_CR18","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/cpdd.1400","volume":"13","author":"P Zuo","year":"2024","unstructured":"Zuo P, Arefayene M, Pan WJ, Freshwater T, Monteleone J. A population pharmacokinetic assessment of the effect of food on selumetinib in patients with neurofibromatosis type 1-related plexiform neurofibromas and healthy volunteers. Clin Pharmacol Drug Dev. 2024;13(7):770\u201381.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"1176_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00228-016-2153-7","volume":"73","author":"AW Dymond","year":"2017","unstructured":"Dymond AW, So K, Martin P, Huang Y, Severin P, Mathews D, et al. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1\/2 inhibitor, in healthy subjects: results from two clinical trials. Eur J Clin Pharmacol. 2017;73(2):175\u201384.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1176_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/03602530902843483","volume":"41","author":"SF Zhou","year":"2009","unstructured":"Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89\u2013295.","journal-title":"Drug Metab Rev"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01176-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01176-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01176-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:10:32Z","timestamp":1764605432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01176-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,26]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1176"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01176-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,26]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"At the time of study conduct, Zhuli Wu, Pu Han, Lei Diao, Yan Tan and Ai-Min Hui were employees of Fosun Pharma, Shanghai, China. Xingli Wang, Hongmei Lin, and Wen Zhong are employees of Fosun Pharma, Shanghai, China. Xiaojie Hu, Jinhu Wang, Wenbin Li, Kang Zeng, Yanling Li, Juan Tao, Zhonghai Guan, Zhuang Kang, Zhongyuan Xu, Yaohui Ma, Liu Yang, Changxing Li, and Xiaoxi Lin declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines and with the approval of the local Institutional Review Board\/Independent Ethics Committee at the leading study site (Shanghai Ninth People\u2019s Hospital, approval no. SH9H-2020-C25-6). All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of the clinical images in Fig.\n                      \n                      was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"De-identified data underlying this work are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"X.L., X.H., Z.W., and A.-M.H. contributed to study design and conception. X.H., Z.W., J.W., W.L., K.Z., Y.L., J.T., Z.G., Z.K., Z.X., Y.M., L.Y., X.W., P.H., and H.L. contributed to study investigation. X.H., Z.W., P.H., H.L., L.D., Y.T., and W.Z. contributed to formal analysis of data. All authors contributed to interpretation of study results, and in the drafting, critical review, and approval of the final version of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}